• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Bp4 S.R.L. sold $62,798 worth of shares (92,900 units at $0.68), decreasing direct ownership by 0.99% to 9,308,799 units (SEC Form 4)

    7/10/25 5:04:30 PM ET
    $MLSS
    Industrial Specialties
    Health Care
    Get the next $MLSS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    BP4 S.r.l.

    (Last) (First) (Middle)
    CORSO VENEZIA 44

    (Street)
    MILAN L6 20121

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    MILESTONE SCIENTIFIC INC. [ MLSS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    07/03/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, Par Value $0.001 07/03/2025 S 50,853 D $0.6698 9,350,846 D
    Common Stock, Par Value $0.001 07/07/2025 S 30,558 D $0.6808 9,320,288 D
    Common Stock, Par Value $0.001 07/08/2025 S 11,489 D $0.6905 9,308,799 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Dr. Pedro Palau, Liquidator 07/10/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MLSS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MLSS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Milestone Scientific Achieves 25% Increase in Revenue for the Second Quarter of 2025

    ROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2025. Neal Goldman, Chairman of the Board, stated, "We are pleased with our revenue performance in the second quarter, delivering a 25% increase in revenue to $2.3 million, driven by strong international dental sales, which more than doubled year-over-year. We also maintained a strong gross margin of 70%, reflecting the benefits of our high-margin dental business and disciplined cost management.

    8/14/25 4:15:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

    ROSELAND, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, August 15th, 2025, to discuss the company's financial results for the second quarter ended June 30, 2025, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 470429. A webcast and replay of the call may be accessed

    8/13/25 11:45:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Appoints Jason Papes as Senior Vice President, Global Head of Sales and Marketing

    ROSELAND. N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Jason Papes as Senior Vice President, Global Head of Sales and Marketing, effective immediately. Mr. Papes brings more than three decades of experience in sales, marketing, and business development within the healthcare industry, including leadership roles at large-cap medical technology companies and successful entrepreneurial ventures. His expertise spans orthopedics, neurology, pain management, and digital imaging, with a track record of building high-perfor

    8/6/25 8:30:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $MLSS
    SEC Filings

    View All

    Large owner Bp4 S.R.L. sold $6,400 worth of shares (10,000 units at $0.64), decreasing direct ownership by 0.11% to 9,298,724 units (SEC Form 4)

    4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

    7/22/25 4:36:09 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Large owner Bp4 S.R.L. sold $62,798 worth of shares (92,900 units at $0.68), decreasing direct ownership by 0.99% to 9,308,799 units (SEC Form 4)

    4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

    7/10/25 5:04:30 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Large owner Bp4 S.R.L. sold $21,882 worth of shares (27,882 units at $0.78), decreasing direct ownership by 0.30% to 9,417,608 units (SEC Form 4)

    4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

    7/2/25 4:31:02 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

    8/5/25 5:15:35 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

    5/19/25 2:05:20 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Milestone Scientific Inc.

    10-Q - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

    5/15/25 4:01:13 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    Leadership Updates

    Live Leadership Updates

    View All

    Milestone Scientific Appoints Jason Papes as Senior Vice President, Global Head of Sales and Marketing

    ROSELAND. N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Jason Papes as Senior Vice President, Global Head of Sales and Marketing, effective immediately. Mr. Papes brings more than three decades of experience in sales, marketing, and business development within the healthcare industry, including leadership roles at large-cap medical technology companies and successful entrepreneurial ventures. His expertise spans orthopedics, neurology, pain management, and digital imaging, with a track record of building high-perfor

    8/6/25 8:30:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Appoints Eric C. Hines as Chief Executive Officer

    ROSELAND, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Eric C. Hines as Chief Executive Officer, effective immediately. Mr. Hines brings more than 25 years of leadership experience in scaling sales-driven enterprise software companies, serving customers across a range of industries, including healthcare. Most recently, he served as President of North America at Ex Libris, a division of Clarivate, where he led operations across the U.S., Canada, and Latin America and increased annual revenue from approximately $50 m

    8/1/25 8:30:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Appoints Highly Accomplished MedTech Executive Shanth Thiyagalingam to Board of Directors

    ROSELAND, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Shanth Thiyagalingam, BMedSc, MMKTG, MBA, has joined its Board of Directors, effective May 14, 2025. Mr. Thiyagalingam brings more than 20 years of global leadership in commercial scaling, product innovation, and strategic execution across the medical device and pharmaceutical industries. Newly appointed board member Shanth Thiyagalingam This appointment further supports Milestone Scientific's strategy to drive adoption of its CompuFlo® Epidural System, broaden access unde

    5/19/25 10:00:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    Financials

    Live finance-specific insights

    View All

    Milestone Scientific Achieves 25% Increase in Revenue for the Second Quarter of 2025

    ROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2025. Neal Goldman, Chairman of the Board, stated, "We are pleased with our revenue performance in the second quarter, delivering a 25% increase in revenue to $2.3 million, driven by strong international dental sales, which more than doubled year-over-year. We also maintained a strong gross margin of 70%, reflecting the benefits of our high-margin dental business and disciplined cost management.

    8/14/25 4:15:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

    ROSELAND, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, August 15th, 2025, to discuss the company's financial results for the second quarter ended June 30, 2025, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 470429. A webcast and replay of the call may be accessed

    8/13/25 11:45:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Achieves 22% Increase in Revenue for the Third Quarter of 2024

    Reports 57% increase in international dental sales for the third quarter of 2024 Advances commercial rollout of CompuFlo® Epidural System across additional pain management clinics following Medicare price assignment in multiple U.S. states ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today reported financial results for the third quarter ended September 30, 2024. Arjan Haverhals, CEO of Milestone Scientific, commented, "We are pleased to report a 22% year-over-year increase in total revenue, reaching $2.5 million for t

    11/14/24 4:30:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care